Literature DB >> 8843258

Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome.

E Benedetti1, A C Gruessner, C Troppmann, B E Papalois, D E Sutherland, D L Dunn, R W Gruessner.   

Abstract

BACKGROUND: Intra-abdominal infections account for 15 percent of technical failures after pancreatic transplantation. Although some data are available about intra-abdominal bacterial infections, no study has analyzed the incidence, treatment, and outcome of intra-abdominal fungal infections. STUDY
DESIGN: We retrospectively studied 445 consecutive pancreatic transplantations--45 percent were simultaneous pancreatic and renal, 24 percent pancreatic after renal, and 31 percent pancreatic transplantations alone--in patients with Type I diabetes mellitus. Donors were cadavers in 92 percent and living relatives in 8 percent. Primary transplantations were done in 80 percent and retransplantation in 20 percent. Of these 445 pancreatic transplantations, 90 percent were bladder-drained, 9 percent enteric-drained, and 1 percent duct-injected. Only symptomatic patients with documented culture-positive intra-abdominal fungal infections were included.
RESULTS: Intra-abdominal fungal infections occurred after pancreatic transplantation in 41 (9.2 percent) of 445 patients. Donor age, but not recipient age, was a significant risk factor. The rate of infections was higher for enteric-drained (21 percent) than for bladder-drained (10 percent) transplantations; for organs donated by living relatives (16 percent) than for those from cadavers (9 percent); and for pancreatic after renal (12 percent) and simultaneous pancreatic-renal (11 percent) than for pancreatic-only (5 percent) recipients. The rate of intra-abdominal fungal infections was 6 percent for recipients who were given antifungal prophylaxis (fluconazole, 400 mg/day for seven days after transplantation) compared with 10 percent for those without prophylaxis. The one-year graft survival rate for recipients with infection was 17 percent compared with 65 percent for those without (p = 0.0001); the survival rate was 70 percent compared with 92 percent for patients with and without infection, respectively (p = 0.0007). In 22 percent of recipients, the infection resolved and graft function persisted; in 58 percent, the infection resolved after transplant pancreatectomy; and in 20 percent, death occurred despite transplant pancreatectomy. Recipients with sole fungal or fungal and bacterial infection (n = 41) were 50 percent less likely to recover with a functioning graft and had a risk of death that was three times higher (p < or = 0.05) than those with sole bacterial infection (n = 48).
CONCLUSIONS: Intra-abdominal fungal infections after pancreatic transplants are associated with high morbidity and mortality rates, significantly higher than for sole bacterial infections. In addition to aggressive treatment, including transplant pancreatectomy and reduction of immunosuppression, efforts must be made toward better prevention of intra-abdominal fungal infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843258

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  24 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Prophylaxis of invasive mycoses in solid organ transplantation.

Authors:  Kyle P Radack; Barbara D Alexander
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

4.  Morphology-Independent Virulence of Candida Species during Polymicrobial Intra-abdominal Infections with Staphylococcus aureus.

Authors:  Evelyn E Nash; Brian M Peters; Paul L Fidel; Mairi C Noverr
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

Review 5.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

6.  Morphogenesis is not required for Candida albicans-Staphylococcus aureus intra-abdominal infection-mediated dissemination and lethal sepsis.

Authors:  Evelyn E Nash; Brian M Peters; Glen E Palmer; Paul L Fidel; Mairi C Noverr
Journal:  Infect Immun       Date:  2014-06-02       Impact factor: 3.441

7.  Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era.

Authors:  C Troppmann; A C Gruessner; D L Dunn; D E Sutherland; R W Gruessner
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

8.  Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction.

Authors:  R J Stratta; A O Gaber; M H Shokouh-Amiri; K S Reddy; R R Alloway; M F Egidi; H P Grewal; L W Gaber; D Hathaway
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

9.  Early and late presentations of graft arterial pseudoaneurysm following pancreatic transplantation.

Authors:  Nir Lubezky; Yaacov Goykhman; Richard Nakache; Ada Kessler; Roni Baruch; Paulina Katz; Itzhak Kori; Joseph M Klausner; Menahem Ben-Haim
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.